JP2015509973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509973A5 JP2015509973A5 JP2014561515A JP2014561515A JP2015509973A5 JP 2015509973 A5 JP2015509973 A5 JP 2015509973A5 JP 2014561515 A JP2014561515 A JP 2014561515A JP 2014561515 A JP2014561515 A JP 2014561515A JP 2015509973 A5 JP2015509973 A5 JP 2015509973A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- formula
- composition according
- metal salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 3
- 239000002184 metal Substances 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- -1 (2-chlorobenzyl) -4-oxo-3,4-dihydroquinazolin-5-yl Chemical group 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229940071138 stearyl fumarate Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610023P | 2012-03-13 | 2012-03-13 | |
| US201261610012P | 2012-03-13 | 2012-03-13 | |
| US61/610,012 | 2012-03-13 | ||
| US61/610,023 | 2012-03-13 | ||
| PCT/GB2013/050624 WO2013136076A1 (en) | 2012-03-13 | 2013-03-13 | Crystalline pi3 kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151378A Division JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性ｐｉ３キナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509973A JP2015509973A (ja) | 2015-04-02 |
| JP2015509973A5 true JP2015509973A5 (OSRAM) | 2016-04-14 |
Family
ID=49160309
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561514A Expired - Fee Related JP6189874B2 (ja) | 2012-03-13 | 2013-03-13 | 新規製薬学的製剤 |
| JP2014561515A Pending JP2015509973A (ja) | 2012-03-13 | 2013-03-13 | 結晶性ｐｉ３キナーゼ阻害剤 |
| JP2017151378A Withdrawn JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性ｐｉ３キナーゼ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561514A Expired - Fee Related JP6189874B2 (ja) | 2012-03-13 | 2013-03-13 | 新規製薬学的製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151378A Withdrawn JP2018008992A (ja) | 2012-03-13 | 2017-08-04 | 結晶性ｐｉ３キナーゼ阻害剤 |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20150099768A1 (OSRAM) |
| EP (2) | EP2825202B1 (OSRAM) |
| JP (3) | JP6189874B2 (OSRAM) |
| KR (2) | KR20140141596A (OSRAM) |
| CN (2) | CN104284679B (OSRAM) |
| AU (2) | AU2013234081B2 (OSRAM) |
| CA (2) | CA2864643A1 (OSRAM) |
| CL (2) | CL2014002386A1 (OSRAM) |
| CO (2) | CO7061079A2 (OSRAM) |
| CR (2) | CR20140417A (OSRAM) |
| CY (1) | CY1118565T1 (OSRAM) |
| DK (1) | DK2834244T3 (OSRAM) |
| EA (2) | EA023715B1 (OSRAM) |
| EC (2) | ECSP14018142A (OSRAM) |
| ES (2) | ES2650791T3 (OSRAM) |
| GT (2) | GT201400182A (OSRAM) |
| HR (1) | HRP20161383T1 (OSRAM) |
| HU (1) | HUE029420T2 (OSRAM) |
| IL (2) | IL233883A0 (OSRAM) |
| IN (2) | IN2014MN01998A (OSRAM) |
| LT (1) | LT2834244T (OSRAM) |
| MX (2) | MX355299B (OSRAM) |
| MY (1) | MY171125A (OSRAM) |
| NI (2) | NI201400100A (OSRAM) |
| NZ (2) | NZ628072A (OSRAM) |
| PE (2) | PE20142342A1 (OSRAM) |
| PH (2) | PH12014501713A1 (OSRAM) |
| PL (1) | PL2834244T3 (OSRAM) |
| PT (1) | PT2834244T (OSRAM) |
| SG (2) | SG11201404519UA (OSRAM) |
| SI (1) | SI2834244T1 (OSRAM) |
| TW (2) | TWI586378B (OSRAM) |
| UA (1) | UA115544C2 (OSRAM) |
| WO (2) | WO2013136075A1 (OSRAM) |
| ZA (2) | ZA201407373B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
| JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
| AR095353A1 (es) | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
| PL3052485T3 (pl) | 2013-10-04 | 2022-02-28 | Infinity Pharmaceuticals, Inc. | Związki heterocykliczne i ich zastosowania |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| UA115296C2 (uk) | 2014-07-04 | 2017-10-10 | Люпін Лімітед | Хінолізинонові похідні як інгібітори pi3k |
| TR201818680T4 (tr) | 2014-07-09 | 2019-01-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | İnhalasyona yönelik formülasyonların hazırlanması için bir proses. |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| SG10202010192YA (en) * | 2016-04-15 | 2020-11-27 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| WO1999028979A2 (en) | 1997-12-02 | 1999-06-10 | Alcatel Usa Sourcing, L.P. | Digital phone system |
| DK1131059T3 (da) * | 1998-11-13 | 2003-06-30 | Jago Res Ag | Tørpulver til inhalation |
| EP1140938B1 (en) | 1999-01-11 | 2003-08-27 | Princeton University | High affinity inhibitors for target validation and uses thereof |
| AU3409399A (en) | 1999-03-05 | 2000-09-28 | Chiesi Farmaceutici S.P.A. | Improved powdery pharmaceutical compositions for inhalation |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| EP1578898A2 (en) | 2001-07-13 | 2005-09-28 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
| WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
| CA2517888C (en) | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
| EP1625165A2 (en) | 2003-04-03 | 2006-02-15 | Protein Design Labs, Inc. | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| JP2009513529A (ja) | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | ステアリン酸マグネシウムを含む医薬製剤 |
| GB0316341D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulations |
| WO2005012221A1 (ja) | 2003-08-04 | 2005-02-10 | Ono Pharmaceutical Co., Ltd. | ジフェニルエーテル化合物、その製造方法および用途 |
| US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
| GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| CA2552664A1 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
| CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| HRP20161751T1 (hr) * | 2004-05-13 | 2017-04-07 | Icos Corporation | Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta |
| JP2008500338A (ja) | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び／又は予防する方法 |
| EP1750715A1 (en) | 2004-06-04 | 2007-02-14 | Icos Corporation | Methods for treating mast cell disorders |
| JP4894518B2 (ja) | 2004-09-13 | 2012-03-14 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| CA2598409A1 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| SI2004654T1 (sl) | 2006-04-04 | 2013-11-29 | The Regents Of The University Of California | Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti |
| CA2909277A1 (en) | 2006-04-04 | 2007-10-11 | Kevan M. Shokat | Kinase antagonists |
| EP2032605A2 (en) | 2006-05-24 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY |
| US8022088B2 (en) | 2006-06-29 | 2011-09-20 | Schering Corporation | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2008058402A1 (en) | 2006-11-17 | 2008-05-22 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| WO2008067219A2 (en) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| CA2684932A1 (en) | 2007-05-09 | 2008-11-20 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| DK2240451T3 (da) | 2008-01-04 | 2017-11-20 | Intellikine Llc | Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| EP2365810A2 (en) | 2008-12-04 | 2011-09-21 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
| US8658648B2 (en) | 2008-12-05 | 2014-02-25 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
| US20110135655A1 (en) | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
| CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| IN2012DN01254A (OSRAM) | 2009-08-05 | 2015-05-15 | Versitech Ltd | |
| GB0918249D0 (en) * | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| WO2011083387A1 (en) | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
| CN201676365U (zh) | 2010-03-29 | 2010-12-22 | 山东京卫制药有限公司 | 带有语音提示的给药吸入装置 |
| CN201692450U (zh) | 2010-06-22 | 2011-01-05 | 于清 | 用于药物输送的高效干粉吸入器 |
| EP2611423B2 (en) | 2010-08-31 | 2022-09-21 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| TR201901644T4 (tr) | 2010-09-30 | 2019-02-21 | Chiesi Farm Spa | İnhalasyon için kuru toz formülasyonlarında magnesyum stearat. kullanımı. |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| CN202154919U (zh) | 2011-05-03 | 2012-03-07 | 王晓明 | 一种防交叉感染雾化吸入装置 |
| TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
-
2013
- 2013-03-13 TW TW102108766A patent/TWI586378B/zh not_active IP Right Cessation
- 2013-03-13 AU AU2013234081A patent/AU2013234081B2/en not_active Ceased
- 2013-03-13 HU HUE13711105A patent/HUE029420T2/en unknown
- 2013-03-13 KR KR1020147026258A patent/KR20140141596A/ko not_active Ceased
- 2013-03-13 EA EA201491675A patent/EA023715B1/ru not_active IP Right Cessation
- 2013-03-13 PL PL13711105T patent/PL2834244T3/pl unknown
- 2013-03-13 JP JP2014561514A patent/JP6189874B2/ja not_active Expired - Fee Related
- 2013-03-13 KR KR1020147026305A patent/KR20140131971A/ko not_active Ceased
- 2013-03-13 US US14/381,273 patent/US20150099768A1/en not_active Abandoned
- 2013-03-13 WO PCT/GB2013/050623 patent/WO2013136075A1/en not_active Ceased
- 2013-03-13 HR HRP20161383TT patent/HRP20161383T1/hr unknown
- 2013-03-13 MX MX2014010991A patent/MX355299B/es active IP Right Grant
- 2013-03-13 SI SI201330362A patent/SI2834244T1/sl unknown
- 2013-03-13 PT PT137111050T patent/PT2834244T/pt unknown
- 2013-03-13 SG SG11201404519UA patent/SG11201404519UA/en unknown
- 2013-03-13 MX MX2014010990A patent/MX357170B/es active IP Right Grant
- 2013-03-13 IN IN1998MUN2014 patent/IN2014MN01998A/en unknown
- 2013-03-13 CN CN201380013848.1A patent/CN104284679B/zh not_active Expired - Fee Related
- 2013-03-13 EA EA201491674A patent/EA025465B1/ru not_active IP Right Cessation
- 2013-03-13 PE PE2014001415A patent/PE20142342A1/es not_active Application Discontinuation
- 2013-03-13 ES ES13711104.3T patent/ES2650791T3/es active Active
- 2013-03-13 WO PCT/GB2013/050624 patent/WO2013136076A1/en not_active Ceased
- 2013-03-13 CA CA 2864643 patent/CA2864643A1/en not_active Abandoned
- 2013-03-13 CN CN201380013851.3A patent/CN104302650B/zh not_active Expired - Fee Related
- 2013-03-13 NZ NZ628072A patent/NZ628072A/en not_active IP Right Cessation
- 2013-03-13 EP EP13711104.3A patent/EP2825202B1/en active Active
- 2013-03-13 AU AU2013234080A patent/AU2013234080B2/en not_active Ceased
- 2013-03-13 SG SG11201404522VA patent/SG11201404522VA/en unknown
- 2013-03-13 IN IN2000MUN2014 patent/IN2014MN02000A/en unknown
- 2013-03-13 JP JP2014561515A patent/JP2015509973A/ja active Pending
- 2013-03-13 TW TW102108767A patent/TWI617561B/zh not_active IP Right Cessation
- 2013-03-13 LT LTEP13711105.0T patent/LT2834244T/lt unknown
- 2013-03-13 ES ES13711105.0T patent/ES2600705T3/es active Active
- 2013-03-13 MY MYPI2014702576A patent/MY171125A/en unknown
- 2013-03-13 PE PE2014001414A patent/PE20141964A1/es not_active Application Discontinuation
- 2013-03-13 CA CA 2864652 patent/CA2864652A1/en not_active Abandoned
- 2013-03-13 US US14/381,289 patent/US9642799B2/en not_active Expired - Fee Related
- 2013-03-13 DK DK13711105.0T patent/DK2834244T3/en active
- 2013-03-13 UA UAA201408662A patent/UA115544C2/uk unknown
- 2013-03-13 EP EP13711105.0A patent/EP2834244B1/en active Active
- 2013-03-13 NZ NZ627963A patent/NZ627963A/en not_active IP Right Cessation
-
2014
- 2014-07-30 IL IL233883A patent/IL233883A0/en unknown
- 2014-07-30 PH PH12014501713A patent/PH12014501713A1/en unknown
- 2014-07-30 IL IL233886A patent/IL233886A/en not_active IP Right Cessation
- 2014-08-27 PH PH12014501922A patent/PH12014501922A1/en unknown
- 2014-08-29 CO CO14190112A patent/CO7061079A2/es unknown
- 2014-08-29 CO CO14190111A patent/CO7051030A2/es unknown
- 2014-09-01 GT GT201400182A patent/GT201400182A/es unknown
- 2014-09-02 GT GT201400183A patent/GT201400183A/es unknown
- 2014-09-05 NI NI201400100A patent/NI201400100A/es unknown
- 2014-09-05 NI NI201400101A patent/NI201400101A/es unknown
- 2014-09-09 CL CL2014002386A patent/CL2014002386A1/es unknown
- 2014-09-09 CL CL2014002385A patent/CL2014002385A1/es unknown
- 2014-09-10 CR CR20140417A patent/CR20140417A/es unknown
- 2014-09-10 CR CR20140416A patent/CR20140416A/es unknown
- 2014-09-10 EC ECIEPI201418142A patent/ECSP14018142A/es unknown
- 2014-09-12 EC ECIEPI201418630A patent/ECSP14018630A/es unknown
- 2014-10-10 ZA ZA2014/07373A patent/ZA201407373B/en unknown
- 2014-10-10 ZA ZA2014/07374A patent/ZA201407374B/en unknown
-
2016
- 2016-11-09 CY CY20161101148T patent/CY1118565T1/el unknown
-
2017
- 2017-05-08 US US15/588,845 patent/US20170239256A1/en not_active Abandoned
- 2017-08-04 JP JP2017151378A patent/JP2018008992A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509973A5 (OSRAM) | ||
| HRP20161383T1 (hr) | Kristalni inhibitori pi3 kinaze | |
| JP7536721B2 (ja) | キナーゼを修飾する１ｈ－ピロロ［２，３－ｂ］ピリジン誘導体の合成 | |
| JP2015509972A5 (OSRAM) | ||
| JP2014524442A5 (OSRAM) | ||
| JP2016537346A5 (OSRAM) | ||
| JP2013541592A5 (OSRAM) | ||
| RU2015132371A (ru) | Твердые формы селективного ингибитора CDK4/6 | |
| JP2018534348A5 (OSRAM) | ||
| JP2017527549A5 (OSRAM) | ||
| JP2018520205A5 (OSRAM) | ||
| JP2012527442A5 (OSRAM) | ||
| JP2016503010A5 (OSRAM) | ||
| JP2015522037A5 (OSRAM) | ||
| JP2015078201A5 (OSRAM) | ||
| JP2013538849A5 (OSRAM) | ||
| JP2016510768A5 (OSRAM) | ||
| JP2022160667A (ja) | アクリジニウム臭化物の製造方法 | |
| JP2020528057A (ja) | ビランテロールトリフェニル酢酸塩の新規な結晶形態及びこれらの調製プロセス | |
| JP2018515527A5 (OSRAM) | ||
| JP2016172741A5 (OSRAM) | ||
| HRP20250660T1 (hr) | Čvrsti oblici ixazomib citrata | |
| JP2012530118A5 (OSRAM) | ||
| JP2018510189A5 (OSRAM) | ||
| ES2716420T3 (es) | Clorhidrato de eliglustat cristalino |